ALVOTECH

NASDAQ: ALVO (Alvotech)

最近更新时间: 03 Jan, 4:27PM

13.26

0.10 (0.76%)

前收盘价格 13.16
收盘价格 13.25
成交量 96,116
平均成交量 (3个月) 117,325
市值 4,003,777,536
价格/销量 (P/S) 8.56
52周波幅
9.15 (-30%) — 18.00 (35%)
利润日期 13 Nov 2024
营业毛利率 -200.30%
营业利益率 (TTM) 46.22%
稀释每股收益 (EPS TTM) -1.85
季度收入增长率 (YOY) 4,399.70%
季度盈利增长率 (YOY) -65.50%
流动比率 (MRQ) 0.240
营业现金流 (OCF TTM) -310.18 M
杠杆自由现金流 (LFCF TTM) -287.74 M
资产报酬率 (ROA TTM) -7.61%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 混合的 混合的
Drug Manufacturers - Specialty & Generic (全球的) 混合的 混合的
股票 Alvotech 混合的 看涨

AIStockmoo 评分

2.5
分析师共识 NA
内部交易活动 NA
价格波动 1.0
技术平均移动指标 2.5
技术振荡指标 4.0
平均 2.50

相关股票

股票 市值 DY P/E(TTM) P/B
ALVO 4 B - - -
ITCI 10 B - - 8.79
LNTH 6 B - 15.29 5.58
KNSA 1 B - - 3.35
HROW 1 B - - 22.53
CRON 768 M - - 0.710

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Growth
内部持股比例 64.01%
机构持股比例 6.04%

所有权

姓名 日期 持有股份
Lodbrok Capital Llp 30 Sep 2024 181,587
Oaktree Fund Advisors, Llc 30 Sep 2024 118,744

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
23 Dec 2024 公告 Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
23 Dec 2024 公告 Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
13 Nov 2024 公告 Alvotech Reports Financial Results for the First Nine Months of 2024
13 Nov 2024 公告 Alvotech Reports Financial Results for the First Nine Months of 2024
07 Nov 2024 公告 Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
07 Nov 2024 公告 Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
04 Nov 2024 公告 European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
04 Nov 2024 公告 European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
30 Oct 2024 公告 Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
30 Oct 2024 公告 Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
25 Oct 2024 公告 Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
25 Oct 2024 公告 Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
22 Oct 2024 公告 Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
22 Oct 2024 公告 Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票